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Background:  Clinical experience with the continuous glucose monitoring systems (CGMS) is limited in Korea. The objective of 
this study is to evaluate the accuracy of the CGMS and the correlation between interstitial fluid and venous plasma glucose level 
in Korean healthy male subjects.
Methods:  Thirty-two subjects were served with glucose solution contained same amount of test food’s carbohydrate and test 
foods after separate overnight fasts. CGMS was performed over 3 days during hopitalization for each subjects. Venous plasma 
glucose measurements were carried out during 4 hours (0, 0.25, 0.5, 0.75, 1, 2, 4 hours) just before and after glucose solution and 
test food load. The performance of the CGMS was evaluated by comparing its readings to those obtained at the same time by the 
hexokinase method using the auto biochemistry machine (Hitachi 7600-110). Also, correlations between glucose recorded with 
CGMS and venous plasma glucose value were examined.
Results:  CGMS slightly underestimated the glucose value as compared with the venous plasma glucose level (16.3 ± 22.2 mg/
dL). Correlation between CGMS and venous plasma glucose values throughout sensor lifetime is 0.73 (regression analysis: slope = 
1.08, intercept = 8.38 mg/dL). Sensor sensitivity can deteriorate over time, with correlations between venous blood glucose and 
CGMS values dropping from 0.77 during 1st day to 0.65 during 2nd and 3rd day.
Conclusion:  The accuracy of data provided by CGMS may be less than expected. CGMS sensor sensitivity is decreased with the 
passage of time. But, from this study, CGMS can be used for glucose variability tendency monitoring conveniently to the Korean.
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INTRODUCTION
For the past 15 years, the use of short acting insulin and long-
acting insulin, insulin pump development, and regular self-
monitoring of blood glucose have played positive roles in reach-
ing the desired level of glycated hemoglobin in diabetics. How-
ever, the fear of patients who still have hypoglycemia is one 
complicated element of blood glucose level regulation that can-
not be overlooked [1]. In other words, normal blood glucose 
regulation is becoming the limiting factor in hypoglycemia in 
patients with diabetes [2]. 
  In this sense, compared to the usual method of checking 
blood glucose levels 3 to 4 times per day, a continuous glucose 
monitoring system (CGMS), a system that provides relatively 
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accurate information regarding blood glucose patterns, dura-
tion, variations, maximum and minimum levels, allows patients 
to be aware of their blood glucose levels at all times. The con-
tinuous measurement throughout a single day or 2 to 3 days 
provides insight to the patterns of blood glucose levels and gives 
warnings to recognize sudden low or high blood glucose levels 
and helps in preventing fatal episodes [2-4]. Furthermore, the 
CGMS is easy to use for patients. A great benefit is insertion 
and wearing the equipment involves minimal discomfort.
  Using CGMS, when implemented previous prospective stud-
ies were examined, the goal glycated hemoglobin level was 
reached more quickly than before CGMS introduction [2,5-10], 
and complications were prevented. However, this benefit was 
only reported in one study. Precisely assessed studies on blood 
glucose regulation were very uncommon [1]. Looking at the 
situation in South Korea, only 17% of diabetics measure their 
blood glucose regularly at medical institutions [11]. Recently, 
raised interest or initiation of maintenance of diabetes has been 
occurring. Owing to the increased education of patients and 
medical professionals about diabetes, it is estimated that more 
patients are measuring their blood glucose regularly at medi-
cal institutions. In addition, in some diabetes centers, using 
CGMS, diurnal changes in interstitial fluid levels were mea-
sured. However limitations include: the increase in elderly, east-
ern traditions, difficulty mounting a new medical device, finan-
cial problems, and domestic problems which make it difficult 
for patients to use. Therefore, clinical experience for the use of 
CGMS is limited, so the reality is that various experiences and 
clinical applications are very difficult. 
  In this study, the authors evaluated the accuracy of CGMS 
and the relationship between the interstitial fluid and venous 
blood glucose level in healthy adults. Additionally, we com-
pared differences of the blood glucose patterns according to 
the experimental diets, with the use and confirmation of flaws 
in the CGMS.
METHODS 
Subjects
The subjects selected for this clinical trial were healthy Korean 
volunteers who satisfied all the selection criteria: 1)  male aged 
20 to 40 years, 2) body weight is 50 kg or more and whithin 
30% of their ideal body weight {ideal body weight = (height 
[cm] - 100) × 0.9}, and 3) agreement of study enrollment. In-
formed consent was obtained from each subject. Exclusion 
criteria include the following: 1) individuals with illness of the 
liver, kidneys, nervous system, respiratory, endocrine, blood, 
tumors, mental illness, or a history of cardiovascular disease, 
2) individuals with a history of gastrointestinal diseases (e.g., 
Crohn’s disease) that can influence nutrient absorption, gas-
trointestinal surgery (excluding simple appendectomy or her-
nia surgery), 3) blood test findings aspartate transaminase 
(AST)/alanine transaminase (ALT) > 1.25 times the upper 
limit of the normal range, 4) individuals having a systolic 
blood pressure under 100 mm Hg and over 150 mm Hg, or in-
dividuals having a diastolic blood pressure under 65 mm Hg 
and over 95 mm Hg, 5) individuals with hypersensitivity to 
experimental diets or having a medical history of clinical al-
lergic reactions, 6) individuals who took prescribed drugs or 
eastern medicines two weeks before the beginning of the study, 
or individuals who took over-the-counter (OTC) medication 
or vitamin supplements (However, candidates may be able to 
participate at the discretion of the examinees), 7) individuals 
who have participated in other clinical trials two months prior 
to the beginning of this study, 8) individuals who have donat-
ed blood up to one month prior to the study, or individuals 
who have donated plasma within the two weeks prior to the 
beginning of the study, 9) individuals who drink 21 drinks/
week or individuals who cannot abstain from alcohol con-
sumption or more during clinical trials, for any other reason 
that the examiner thought that participants’ participation 
would be irrelevant. A 4 × 4 cross-examination was carried 
out on a total of 32 patients. Statistical administration oc-
curred in groups of eight.
Methods
The study was performed in open-label, 4-treatment, 4-order, 
4-time frame crossover design (Table 1); appropriate candi-
dates were selected through an interview, physical exam, and 
disease screening 4 weeks (D-28 to D-1) prior to the clinical 
trial and a random assignment was carried out one day prior 
(D-1) to the first day of the study.
  For the first period of clinical trial (period 1), study subjects 
were admitted to the Clinical Trial Center for Functional Foods 
in Chonbuk National University Hospital by 7:00 PM on the 
1st day. The subjects fasted with the exception of drinking wa-
ter after the initial dinner that was provided by the center. At 
approximately 9:00 AM on the 2nd day, all the subjects who 
had been fasting consumed a control diet based on their ran-
domly assigned group. A control diet was composed of the 352
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same amount of glucose with the carbohydrate content in cor-
responding test meal. Caloric and nutritional composition of 
each test meal is as follows: Korean 1 (Bibimbap) 588 kcal 
(carbohydrates 86.1 g, protein 24.6 g, and fat 16.53 g), Korean 
2 (Kimbap) 598.7 kcal (carbohydrates 83.1 g, protein 27.6 g, 
and fat 17.14 g), Western 1 (pork cutlet) 602.2 kcal (carbohy-
drates 66.4 g, protein 28.4 g, and fat 23.2 g), Western 2 (ham-
burger) 586 kcal (carbohydrates 63.2 g, protein 30.6 g, and fat 
23.2 g). The ingredients of the test meal were produced in the 
same region to ensure the consistency of the quality. They were 
also stored for a minimal amount of time within the expiration 
date. The cooking methods were also kept consistent by estab-
lishing a standard method for meal preparation regarding in-
tensity of the cooking fire and cooking time. This standard was 
used for each preparation. The study subjects consumed the 
provided control diet within 2 minutes. 
  They were prohibited from consuming anything besides 
water after dinner on the 2nd day and provided the test meal 
on 9 AM in the next morning according to the group. The menu 
of each test meal was designed to include representative dishes 
for common types of cuisine: Korean 1 (Bibimbap), Korean 2 
(Kimbap), Western 1 (pork cutlet), and Western 2 (hamburg-
er) (the study subjects were instructed to consume the test 
meal within 15 minutes). After the end of the period 1, all the 
subjects were discharged and 6-day’s resting period was fol-
lowed by the period 2. For the period 2, subjects were admit-
ted again and provied the control diet and test meal according 
to the same method in period 1. Period 3 and 4 were carried 
out in sequence with intervening 6-day’s resting period. 
  The self-monitoring of blood glucose unit used for continu-
ous blood glucose measurement needed for the study was a 
CGMS model from Medtronic (Northridge, CA, USA). Data 
was collected by inserting the blood sugar sensor under the skin 
using plasma calibration with an auto biochemistry machine 
(Hitachi 7600-11; Hitachi, Tokyo, Japan) which was measured 
and analyzed using the hexokinase method. For this process, 
blood glucose measurements were taken 4 times a day and in-
putted into the CGMS. Continuous blood glucose measure-
ments were taken on day one (and on the 2nd, 8th, 9th, 15th, 
16th, 22nd, 23rd day) between hour 0 (before the meal) and 
hour 4 every 5 minutes. Blood samples for measurement of 
blood glucose and insulin was taken on day one (and 2nd, 8th, 
9th, 15th, 16th, 22nd, 23rd day) at hour 0 (before the meal), 
hour 0.25, hour 0.5, hour 0.75, hour 1, hour 2, and hour 4. A 
blood sample of 1 mL was taken from brachial veins without 
the use of a catheter due to the characteristics of the research 
methods. 
Statistical analysis
Statistical analysis was performed using the following meth-
ods using a significance level of 0.05 (average ± standard devi-
ation) with SPSS
 (SPSS Inc., Chicago, IL, USA), SAS (SAS In-
stitute, Cary, NC, USA) and/or S-plus (TIBCO, Palo Alto, CA, 
USA) statistical software. Demographic statistical analysis of 
participants of the clinical trial was carried out to ensure ran-
dom sampling. Participant age, height, body weight, and alco-
hol and caffeine consumption information was collected for 
demographic statistical analysis. 
  Analysis of variance (ANOVA) was used for continuous vari-
ables, and Fisher’s exact test was used for categorical variables. 
The correlation and significance between the glucose level mea-
sured from the reference sample of venous blood, and that from 
CGMS were analyzed using linear regression analysis. 
  Each measured level was marked as a distribution point us-
ing a Clarke error grid analysis; areas A and B are clinically ac-
ceptable regions and areas C, D, and E are regions which are 
considered unsafe or unacceptable. 
RESULTS
Clinical characteristics of the participants
Thirty-two adult males were randomly assigned to participate 
in this study. Mean age was 23.9 ± 1.5 years, mean height was 
173.9 ± 5.3 cm, mean body weight was 64.8 ± 6.3 kg, fasting 
plasma glucose/insulin was 88.3 ± 5.6 mg/dL/3.6 ± 1.7 uU/mL, 
respectively, blood urea nitrogen (BUN)/Creatinine was 13.7 
± 2.8 mg/dL/0.97 ± 0.1 mg/dL, AST/ALT was 20.3 ± 8.6 IU/
L/17.9 ± 13.4 IU/L, and the lipid profile (cholesterol/triglycer-
ide/HDL/LDL) was 159.6 ± 26.6 mg/dL/103.3 ± 40.9 mg/
Table 1.  Open label, 4-treatment, 4-sequence, 4-perioid 
crossover study
Treatment No. Period 1  Period 2  Period 3  Period 4 
Group 1  8  Control 
Test meal 1 
Control 
Test meal 2 
Control 
Test meal 3 
Control 
Test meal 4 
Group 2  8  Control 
Test meal 4 
Control 
Test meal 1 
Control 
Test meal 2 
Control 
Test meal 3 
Group 3  8  Control 
Test meal 3 
Control 
Test meal 4 
Control 
Test meal 1 
Control 
Test meal 2 
Group 4  8  Control 
Test meal 2 
Control 
Test meal 3 
Control 
Test meal 4 
Control 
Test meal 1 353
The correlation and accuracy of CGMS
Korean Diabetes J 2010;34:350-358 www.e-kdj.org
dL/51.9 ± 8.0 mg/dL/96.4 ± 26.9 mg/dL, respectively. The 
mean value for body mass index was 20.8 ± 1.5 (Table 2). Per-
sonal medical history, physical examination, and baseline 
blood examination showed no associated diseases.
The comparison of the glucose profiles from CGMS and 
venous plasma glucose values of each group
Fig. 1 shows the glucose profiles from CGMS and venous plas-
ma glucose for each group, and the patterns and relationship 
between them. Values of postprandial venous plasma glucose 
levels of all groups were between 130 to 190 mg/dL. Plasma 
glucose 4 hours after eating was measured to be 60 to 90 mg/
dL. The highest blood glucose measurement was 171 mg/dL, 
and the lowest blood glucose measurement was 71 mg/dL. The 
CGMS showed that peak postprandial glucose level was 120 to 
140 mg/dL which was lower than that from plasma and the time 
to the peak glucose level was 45 to 75 minutes which was longer 
than 30 to 60minutes in plasma value. With the CGMS, the 
highest value was measured to be 131 mg/dL, and the lowest 
value was measured to be 71.6 mg/dL. The overall distribution 
pattern of intravenous glucose and CGMS values were similar 
in each group.
The comparison of the glucose level according to the 
control diet and test meal
Looking at the CGMS and venous plasma glucose patterns from 
different types of diets (Fig. 2), the pattern of venous plasma 
glucose in all control diet and test meal reached approximately 
100 to 190 mg/dL 30 to 45 minutes after consumption and 
then decreased in 60 minutes after meal, and normal fasting 
glucose level were seen 4 hours after meal. Additionally, the 
control diet resulted in the highest postprandial blood glucose 
level, and also the lowest postprandial venous plasma glucose 
level in all four groups, but it had no statistical significance. 
  Additionally, glucose value distribution measured with 
CGMS showed the similar pattern of postprandial increament 
in plasma glucose level, however, time to peak level was 45 to 
60 minutes. Four hours after eating, the glucose level were 
similar to that from plasma again (Fig. 3). The highest and 
lowest glucose level in CGMS were also seen in the control 
diet and there was no significant difference in the value from 
CGMS and plasma in each group.
The relationship and correlation between the glucose 
profiles from CGMS and venous plasma glucose 
measurement values
During the entire experimental period for all of the groups, 
when comparing the glucose level measured with CGMS and 
venous plasma glucose level, postprandial blood glucose pat-
terns and even fasting plasma glucose level patterns decreased 
in a similar fashion. The time lag phenomenon in the peak 
postprandial glucose level between the CGMS value and plas-
ma glucose were seen in gll group and all kinds of diet. Addi-
tionally, the difference between each of the CGMS and venous 
plasma glucose values for hyperglycemia period (45 to 60 
minutes after eating), and hyperglycemia period (0 to 30 mi-
Table 2.  Baseline characteristics of the patients
Group 1 Group 2 Group 3 Group 4 Total
Age, yr  24.0 ± 1.5 23.8 ± 1.9 24.0 ± 0.9 24.0 ± 1.8 23.9 ± 1.5
Height, cm  177.1 ± 6.8 174.3 ± 5.2 172.4 ± 3.0 172.0 ± 5.0 173.9 ± 5.3
Body weight, kg 70.6 ± 6.0 61.9 ± 4.8 63.0 ± 5.5 63.7 ± 6.0 64.8 ± 6.3
Glucose, mg/dL  91.25 ± 6.3 85.4 ± 6.9 87.6 ± 3.6 88.8 ±4.0 88.3 ± 5.6
Insulin, µIU/mL  3.81 ± 1.6 3.14 ± 1.1 4.35 ± 2.5 3.00 ± 1.2 3.6 ± 1.7
BUN, mg/dL  13.5 ± 2.5 14.6 ± 4.2 14.6 ± 2.1 12.1 ± 1.1 13.7 ± 2.8
Creatinine, mg/dL  0.92 ± 0.1 0.94 ± 0.1 1.02 ± 0.1 0.99 ± 1.0 0.97 ± 0.1
AST, IU/L  19.8 ± 12.6 17.4 ± 3.4 18 ± 3.1 26.3 ± 9.7 20.3 ± 8.6
ALT, IU/L  20.4 ± 22.0 11.4 ± 3.5 16.1 ± 7.0 23.9 ± 12.3 17.9 ± 13.4
Cholesterol, mg/dL  163.6 ± 28.3 154.5 ± 26.0 154.4 ± 21.1 165.9 ± 33.0 159.6 ± 26.6
TG, mg/dL     118.8 ± 37.2 76.9 ± 20.7 88 ± 26.0 129.7 ± 53.1 103.3 ± 40.9
BMI, kg/m
2 21.25 ± 1.4 20.12 ± 1.6 20.75 ± 1.7 21.12 ± 1.4 20.8 ± 1.5
BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; TG, triglyceride; BMI, body mass index.354
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nuites after eating and 2 to 4 hours after eating) 34 ± 8.23 mg/
dL, and 2.9 ± 4.94 mg/dL respectively, which confirmed that 
the accuracy in the hyperglycemic period was declining. The 
value from CGMS was lower than venous plasma glucose in 
all the time-section (16.3 ± 22.2 mg/dL). The correlation value 
between CGMS and venous plasma glucose was 0.73 (Fig. 4; 
regression analysis: slope = 1.08, intercept = 8.38 mg/dL). Ad-
ditionally, correlation of these values, on the 1st day of clinical 
trials was 0.77, and on the 2nd day, it decreased to 0.65 (Figs. 5 
and 6). These results were analyzed by error grid analysis (n = 
1,568). Area A and area B are located at 95.4%, and CGMS’s 
usefulness was confirmed (Fig. 7).
DISCUSSION
One benefit of the CGMS is that it can provide more informa-
tion on the fluctuations of blood glucose. In other words, when 
blood glucose cannot be pin pointed, CGMS provides more 
benefits than intermittent methods of measuring blood glu-
cose [10]. This benefit can greatly reduce the incidence of com-
plications in uncontrolled blood glucose, and patients’ con-
cerns are minimized, and it allows for more active blood glu-
Fig. 1.  (A) group 1, (B) group 2, (C) group 3, and (D) group 4. The relation between continuous glucose monitoring system 
(CGMS) and venous blood glucose levels according to the subject groups. CGMS slightly underestimated the glucose value as 
compared with the venous plasma glucose level. “Time-lag” is observed. However, between each group were similar to venous 
glucose and CGMS aspects. Data was shown as mean ± standard deviation. Rc: Control , Rt: Test meal (R: Glucose from CGMS 
vs. Blood plasma glucose).
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cose regulation. However, as previously mentioned, utilizing 
CGMS to care for patients may not be practical. In reality, clini-
cal experience in utilizing CGMS is minimal in Korea.
  Through this clinical trial, authors discovered that the result 
of CGMS was very similar to the venous plasma glucose level, 
and the correlation between CGMS and the value of venous 
plasma glucose level was relatively accurate. These points ade-
quately explained the general benefits of the CGMS. As a result, 
previous reports regarding the accuracy of the CGMS are con-
sidered to be similar [12-16], and it appears that using the 
CGMS in the future in Korean patients with diabetes can oc-
cur without difficulty.
  There are reports that state there is no proof that CGMS is 
better at regulating blood glucose and metabolism when mea-
suring and comparing venous blood glucose levels [17], but 
there are reports that show the benefits of CGMS in practice in 
reaching target glycated hemoglobin levels and adjusting it to 
appropriate levels [1,2,5-10]. Therefore, it is thought that the 
domestic application of CGMS should be more active, so that 
research and reporting similar to this can be more active.
  However, when this study was compared with the results of 
the main study that was published prior to this, some were able 
to confirm the significance level and the decline of the accura-
cy on the error grid in zones A and B at 98.4% [12] vs. 95.4%. 
However, there were a relatively small number of subjects and 
a short follow-up period. A study involving more patients would 
  Contol diet (CGMS)  Test meal (CGMS)  Contol diet (Plasma glucose)  Test meal (Plasma glucose)
Fig. 2.  (A) Korean meal 1, (B) Korean meal 2, (C) Western meal 1, and (D) Western meal 2. The relation between continuous 
glucose monitoring system (CGMS) and  venous plasma glucose levels according to the meals. When compared by each diet, ve-
nous glucose and CGMS levels showed similar patterns that did not differ significantly. Data was shown as mean ± standard de-
viation. Rc: Control , Rt: Test meal (R: Glucose from CGMS vs. Blood plasma glucose).
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be required for further explanation.
  When the CGMS measured values and venous plasma glu-
cose concentration of each group is compared, no significant 
difference was observed in the overall changes of blood glucose. 
Although blood glucose values measured with CGMS was not 
statistically significant, it showed a lower trend, which in this 
study; target participants were not patients with chronic dis-
eases including diabetes, but healthy adult male patients. In ad-
dition, a comparison with diabetes patients must also be made.
CGMS did not show statistically significant differences between 
implementing control diet and experimental diet for each diet 
group and intravenous glucose. Also, we think this because 
this is a study implemented by targeting non-diabetes healthy 
male subjects. In the future, the importance of the glycemic 
index and glycemic load of this diet group is studied, but it is 
thought to be utilizable.
  When CGMS results were compared with the venous plas-
ma glucose concentrations, CGMS’s time lag was observed. 
Glucose achieves equilibrium through interstitial fluid in the 
blood through this, and at this time, it is a physiological pro-
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Fig. 4.  Correlation between continuous glucose monitoring 
system (CGMS) and venous plasma glucose levels (regression 
analysis: slope = 1.08, intercept = 8.38 mg/dL). 
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Fig. 6.  Correlation between continuous glucose monitoring 
system (CGMS) and venous plasma glucose levels (2nd day, 
regression analysis: slope = 1.08, intercept = 8.38 mg/dL).
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system (CGMS) and venous plasma glucose levels (1st day, re-
gression analysis: slope = 1.08, intercept = 8.38 mg/dL).
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cess [18]. It is assumed that CGMS measurement values dur-
ing hypoglycemia or sudden pattern changes may be impre-
cise [19]. 
  In addition, the sensor’s sensitivity decreased over time, and 
the accuracy decline was observed. These results have been re-
ported in previous CGMS clinical trials [12,13]: bleeding and 
irritation of the skin between sensors [18], adsorption of tissue 
around the sensor, localized accumulation of inflamed cells, 
and fibrous encapsulation are thought to have caused these re-
sults [20-22]. Using corticosteroid spray on the sensors for all 
treatments can reduce these problems [9]. Further clinical tri-
als are required to confirm this.
  In conclusion, this study investigated the data obtained from 
a CGMS and venous plasma glucose level, which was confirmed 
to have a high correlation. There was no statistical difference 
observed in the changing patterns in blood glucose from food 
types and experimental diets, and it was confirmed that there 
are still problems such as the decrease in time lag and sensor 
sensitivity. Additionally, it is reported that CGMS was performed 
in many previous studies involving diabetes patient groups; 
especially type 1 diabetics, pregnant patients, and special cases 
such as patients on dialysis. In this clinical trial, healthy adults 
were used because the accuracy of the correlation between 
changes in glucose is more credible. However, since it is used 
as such on diabetes patients, there are limits to the interpreta-
tion of the results. Additionally, the number of participants in 
this study was small. For increased reliability and representa-
tion of the clinical trials, more personnel are needed. Others 
cannot comment on the accuracy of all CGMS’s between CGMS 
machines; and because differences could not be assessed, future 
studies should include the CGMS used in this study so each 
machine’s correlation and accuracy can be compared. Howev-
er, through this clinical trial, the authors were able to confirm 
that CGMS would be very useful in the domestic market to 
figure out changes in blood glucose and distribution states as 
levels of blood glucose measured by CGMS were very similar 
to venous blood. Therefore, continuous research should be con-
ducted so that CGMS can be used as a method to increase the 
success of reaching target blood glucose level and also to de-
termine appropriate controlling methods for blood glucose.
REFERENCES
1. Juvenile Diabetes Research Foundation Continuous Glucose 
Monitoring Study Group. The effect of continuous glucose 
monitoring in well-controlled type 1 diabetes. Diabetes Care 
2009;32:1378-83.
2. Cryer PE. Banting lecture. Hypoglycemia: the limiting factor in 
the management of IDDM. Diabetes 1994;43:1378-89.
3. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous 
glucose monitoring system is useful for detecting unrecognized 
hypoglycemias in patients with type 1 and type 2 diabetes but 
is not better than frequent capillary glucose measurements for 
improving metabolic control. Diabetes Care 2003;26:1153-7.
4. Ludvigsson J, Hanas R. Continuous subcutaneous glucose 
monitoring improved metabolic control in pediatric patients 
with type 1 diabetes: a controlled crossover study. Pediatrics 
2003;111(5 Pt 1):933-8.
5. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith 
GJ, Murtfeldt R, Garg SK. Continuous subcutaneous glucose 
monitoring in children with type 1 diabetes. Pediatrics 2001; 
107:222-6.
6. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tam-
borlane WV. Limitations of conventional methods of self-mon-
itoring of blood glucose: lessons learned from 3 days of contin-
uous glucose sensing in pediatric patients with type 1 diabetes. 
Diabetes Care 2001;24:1858-62.
7. Danne T, Deiss D, Hopfenmuller W, von Schutz W, Kordonouri 
O. Experience with insulin analogues in children. Horm Res 
2002;57(Suppl 1):46-53.
8. Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, 
Galatzer A, Phillip M. Glycemic patterns detected by continu-
Fig. 7.  Correlation between continuous glucose monitoring 
system (CGMS) and venous plasma glucose levels using the 
Clarke error grid analysis (n = 1,568); 95.4% measures were 
within zones A and B.
250
200
150
100
50
0
0  50  100  150  200  250
Plasma glucose levels (mg/dL)
G
l
u
c
o
s
e
 
l
e
v
e
l
s
 
o
f
 
t
h
e
 
C
G
M
S
 
(
m
g
/
d
L
) A
A
B
B
C
C
D D
E
E358
Baek YH, et al.
Korean Diabetes J 2010;34:350-358 www.e-kdj.org
ous subcutaneous glucose sensing in children and adolescents 
with type 1 diabetes mellitus treated by multiple daily injections 
vs continuous subcutaneous insulin infusion. Arch Pediatr Ad-
olesc Med 2004;158:677-84.
9. Bolinder J, Ungerstedt U, Arner P. Long-term continuous glu-
cose monitoring with microdialysis in ambulatory insulin-de-
pendent diabetic patients. Lancet 1993;342:1080-5.
10. Klonoff DC. Continuous glucose monitoring: roadmap for 21st 
century diabetes therapy. Diabetes Care 2005;28:1231-9.
11. Rhee SY, Kim YS, Oh S, Choi WH, Park JE, Jeong WJ. Diabcare 
Asia 2001-Korea: country report on outcome data and analysis. 
Korean J Intern Med 2005;20:48-54.
12. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, 
McGarraugh GV. Accuracy of the 5-day Free Style Navigator 
Continuous Glucose Monitoring System: comparison with 
frequent laboratory reference measurements. Diabetes Care 
2007;30:1125-30.
13. Gross TM, Mastrototaro JJ. Efficacy and reliability of the contin-
uous glucose monitoring system. Diabetes Technol Ther 2000; 
2 Suppl 1:S19-26.
14. Gross TM, Ter Veer A. Continuous glucose monitoring in pre-
viously unstudied population subgroups. Diabetes Technol 
Ther 2000;2 Suppl 1:S27-34.
15. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White 
NH, Mastrototaro JJ. Performance evaluation of the MiniMed 
continuous glucose monitoring system during patient home 
use. Diabetes Technol Ther 2000;2:49-56.
16. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continu-
ous glucose monitoring used to adjust diabetes therapy im-
proves glycosylated hemoglobin: a pilot study. Diabetes Res 
Clin Pract 1999;46:183-90.
17. Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel 
AP, Tobian J, Gross T, Mastrototaro J. Use of the Continuous 
Glucose Monitoring System to guide therapy in patients with 
insulin-treated diabetes: a randomized controlled trial. Mayo 
Clin Proc 2004;79:1521-6.
18. Sternberg F, Meyerhoff C, Mennel FJ, Mayer H, Bischof F, Pfei-
ffer EF. Does fall in tissue glucose precede fall in blood glucose? 
Diabetologia 1996;39:609-12.
19. Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ. Physiologi-
cal differences between interstitial glucose and blood glucose 
measured in human subjects. Diabetes Care 2003;26:2405-9.
20. Gerritsen M, Jansen JA, Lutterman JA. Performance of subcu-
taneously implanted glucose sensors for continuous monitor-
ing. Neth J Med 1999;54:167-79.
21. Gerritsen M. Problems associated with subcutaneously implant-
ed glucose sensors. Diabetes Care 2000;23:143-5.
22. Gerritsen M, Jansen JA, Kros A, Vriezema DM, Sommerdijk 
NA, Nolte RJ, Lutterman JA, Van Hovell SW, Van der Gaag A. 
Influence of inflammatory cells and serum on the performance 
of implantable glucose sensors. J Biomed Mater Res 2001;54: 
69-75.